AOD9604

AOD9604 research peptide primarily promotes lipolysis in adipose tissue while inhibiting lipogenesis, mimicking the fat-metabolizing domain of hGH without engaging the full growth hormone receptor or altering IGF-1 production. Furthermore, it appears to enhance beta-3 adrenergic receptor expression and sensitivity in adipocytes, thereby increasing cyclic AMP levels, activating hormone-sensitive lipase, and facilitating fatty acid oxidation for energy utilization. Additionally, laboratory models show elevated plasma glycerol as an index of lipolysis, alongside reduced body fat accumulation without impacting insulin sensitivity or carbohydrate metabolism. These selective actions, observed in obese rodent studies and cellular assays, contribute to observed metabolic shifts, with recent research emphasizing its reassuring profile for targeted lipid pathway investigations free from typical hGH-associated drawbacks.

• Lipolysis and fat oxidation pathway studies

• Lipogenesis inhibition mechanism analysis

• Adipose tissue metabolism investigations

• Beta-3 adrenergic receptor modulation research

• Body weight regulation and energy expenditure evaluations

• Metabolic homeostasis without IGF-1 disruption examinations

• M et al. Endocrinology. 2001;142(12):5182-5189. 

• Ng FM et al. Horm Res. 2000;53(6):274-278.

• Heffernan MA et al. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449.

• Moré MI. J Obes Endocrinol Metab. 2014;2(1):1-8. 

• Heffernan M et al. Endocrinology. 2001;142(12):5182-5189.